Brainsway Ltd., a leader in advanced neurostimulation treatments, has announced a significant strategic collaboration with Inland Psychiatry Medical Group (IPMG). This partnership aims to accelerate the innovative application of interventional psychiatry treatments across Southern California.
The collaboration is set to enhance mental health care services by installing BrainsWay's Deep TMS systems at IPMG clinics. This initiative reflects a shared commitment to improving patient outcomes through advanced therapeutic solutions.
Background
Founded in 2003, Brainsway Ltd. is a global leader in non-invasive neurostimulation treatments for mental health disorders. The company operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Brainsway is listed on both the Nasdaq and OTC exchanges under the tickers BWAY and BRSYF, respectively. The company has been actively filing reports, including recent submissions of Form 6-K, with the latest filed on October 19, 2026.
What the Filing Says
The recent filing indicates that Brainsway has entered into a multisystem order with IPMG for the installation of Deep TMS systems. The collaboration also includes plans for various scientific and clinical research projects aimed at expanding interventional psychiatry.
Impact
This partnership may significantly affect patients seeking innovative mental health treatments in Southern California. By integrating BrainsWay's advanced technology into IPMG's services, both organizations aim to enhance the quality of care provided to patients suffering from mental health disorders.
What's Next
The filing does not say what happens next, but the collaboration is expected to lead to further developments in interventional psychiatry.